Delving into the Latest Updates on Metronidazole Benzoate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-(2-Methyl-5-nitroimidazol-1-yl)ethyl benzoate, Benzoyl metronidazole, Benzoylmetronidazole

+ [3]

Target-

Mechanism

DNA synthesis inhibitors

Therapeutic Areas

Infectious DiseasesDigestive System DisordersSkin and Musculoskeletal Diseases+ [2]

Active Indication

AmebiasisAnaerobic bacterial infectionBalantidiasis+ [4]

Inactive Indication

Gastrointestinal motility disorder

Originator Organization-

Active Organization-

Inactive Organization

Tillotts Pharma AG

Drug Highest PhaseApproved

First Approval Date

CN (26 Nov 2002),

AmebiasisAnaerobic bacterial infectionBalantidiasis+ [4]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC13H13N3O4

InChIKeyCUUCCLJJOWSASK-UHFFFAOYSA-N

CAS Registry13182-89-3

This is a Phase I, open label, single-site trial to evaluate the in vivo release characteristics in the gastrointestinal tract of metronidazole benzoate capsules designed to disintegrate in the large intestine. This will be examined by means of metronidazole plasma levels and scintigraphic images in healthy subjects. Overall, nine subjects will be evaluated for each formulation prototype. Two formulation prototypes will be investigated. Each subject will receive one radio-labelled capsule only.

Start Date25 Nov 2016

Sponsor / Collaborator

Tillotts Pharma AG

[+3]

NCT02146209

/ CompletedPhase 1

Comparative Randomized, Single Dose, Three-Period Crossover Open-Label Study to Determine the Bioequivalence Of Terix Labs Ltd Metronidazole Benzoate (400 mg Metronidazole Per Sachet Oral Granules (Formula A)) Relative to 500 mg From Sanofi-aventis Flagyl 125 mg/5 ml (125 mg Metronidazole Per 5 ml Suspension (Formula B)) and Zentiva Flagyl™ 400 mg Tablets (400 mg Metronidazole Per Film Coated Tablets (Formula C)) , After an Oral Administration to Healthy Adults Under Fasting Conditions

The purpose of this study is to determine whether Terix Labs Ltd Metronidazole benzoate (400 mg Metronidazole Per Sachet Oral Granules) is bioequivalent to 500 mg Sanofi-aventis Flagyl 125 mg/5 ml (125 mg Metronidazole Per 5 ml Suspension) and to Zentiva Flagyl™ 400 mg Tablets (400 mg Metronidazole Per Film Coated Tablets).

Start Date01 Jun 2014

Sponsor / Collaborator

Verisfield (UK) Ltd.

NCT01938183

/ CompletedPhase 2IIT

Full-mouth Periodontal Debridement With or Without Adjunctive Metronidazole Gel in Smoking Patients With Chronic Periodontitis

Hypothesis: metronidazole gel applied topically after periodontal debridement in smokers volunteers could improve clinical parameters when compared to metronidazole tablets + periodontal debridement. Method: 30 smokers with chronic periodontitis were randomly assigned into 3 groups: periodontal debridement combined with 3 g placebo gel; periodontal debridement combined with daily topical application of 3 g metronidazole benzoate gel (15%); and periodontal debridement combined with a daily single dose of 750 mg metronidazole. Clinical parameters evaluated were visible plaque, gingival bleeding, probing pocket depth and relative attachment level.

Start Date01 Nov 2006

Sponsor / Collaborator

University of Campinas

100 Clinical Results associated with Metronidazole Benzoate

Login to view more data

100 Translational Medicine associated with Metronidazole Benzoate

Login to view more data

100 Patents (Medical) associated with Metronidazole Benzoate

Login to view more data

160

Literatures (Medical) associated with Metronidazole Benzoate

01 Mar 2025·Journal of Inorganic Biochemistry

Co(II), Cu(II), and Zn(II) thio-bis(benzimidazole) complexes induce apoptosis via mitochondrial pathway

Article

Author: Rárová, Lucie ; Rigamonti, Luca ; Antal, Peter ; Strnad, Miroslav ; Gonzalez, Gabriel ; Kvasnicová, Marie ; Kuchár, Juraj ; Kopel, Pavel

The copper(II), cobalt(II), and zinc(II) complexes with 2-(1H-benzimidazol-2-ylmethylsulfanylmethyl)-1H-benzimidazole (tbb) and 2-[2-[2-(1H-benzimidazol-2-yl)ethylsulfanyl]ethyl]-1H-benzimidazole (tebb), [Cu(tbb)Cl₂] (1), [Co(tbb)Cl₂] (2), [Zn(tbb)Cl₂] (3), [Cu(tebb)Cl(H₂O)]Cl (4), [Co(tebb)Cl₂]_n·nCH₃OH (5) and [Zn(tebb)Cl(H₂O)]Cl (6), have been prepared and evaluated for antiproliferative activity. The structure of (4) was proved by X-ray diffraction crystallography. The coordination compounds were tested for their cytotoxic activities in cancer cell lines in vitro. The lower IC₅₀ values were obtained for Co(II), Cu(II), and Zn(II) complexes with tebb in comparison with tbb complexes. Complex 2 showed strong antiproliferative selectivity for leukemia CEM cells and nontoxicity towards other tested cell lines and normal human cells (BJ and RPE-1). Proapoptotic activity of 2 and 5 were weaker than positive control cisplatin, but the big advantage of these complexes was their zero-cytotoxicity for normal healthy cells in contrast to the high cytotoxicity of cisplatin. The activation of apoptotic initiation phase was detected in neuroblastoma cancer cell line SH-SY5Y where 5 was cytotoxic without fragmentation of cells. Interestingly, complexes 5, 6, and tebb, together with cisplatin, dramatically impaired the mitochondrial membrane potential of SH-SY5Y after 72 h. Taken together, we demonstrated that our compounds trigger apoptosis via the mitochondrial pathway.

09 Dec 2024·Inorganic Chemistry

Selective Electrocatalytic Oxidation of Ammonia by Ru-dpp Complexes Containing Aromatic Nitrogen Donor as Axial Ligand

Article

Author: Ding, Xiao-Lv ; Zhong, Si-Dan ; Chen, Guo ; He, Piao ; Zhao, Shan ; Yi, Xiao-Yi ; Cheng, Tao ; Yang, Shun-Ping ; Zhang, Xi

Inspired by the rapid growth of Ru-based complexes as molecular ammonia oxidation catalysts, we propose novel Ru-dpp complexes bearing a nitrogen donor as the axial ligand into the ammonia oxidation catalysts family. Herein, a series of Ru-dpp complexes [Ru(K³-N,N',N″-dpp)(bpy)(L)]·PF₆ (where Hdpp = 2-[5-(pyridin-2-yl)-1H-pyrrol-2-yl]pyridine; bpy = 2,2'-bipyridine; L = pyridine (Ru-py); 4-methylpyridine (Ru-pic); pyrimidine (Ru-pmd); isoquinoline (Ru-isoq)) containing aromatic nitrogen donor axial ligand are synthesized and fully characterized by NMR, IR, and ESI-MS. The structural analysis displays that dpp^- as a pincer ligand coordinates to ruthenium, and nitrogen donor L binds to ruthenium at an axial ligand. The reaction of Ru-L with ammonia generates ammonia-ligated Ru-L-NH₃ complexes, which are monitored by NMR and UV-vis spectra. The electrochemical properties are studied by cyclic voltammetry and density functional theory calculation. These titled complexes have good electrocatalytic performances for selective oxidation of ammonia into hydrazine at 0.6 V versus Cp₂Fe^+/0 onset potential. The turnover frequency of N₂H₄ formation is 326.4-393.4 h^-1, and the faraday efficiency of generating hydrazine exceeds 97%. The N-N formation mechanism via bimolecular coupling of ruthenium amide/imide is proposed. The aminyl character of ruthenium amide intermediate is confirmed by EPR spectra.

01 Mar 2024·International Journal of Biological Macromolecules

Zein and hydroxypropyl methylcellulose acetate succinate microfibers combined with metronidazole benzoate and/or metronidazole-incorporated cellulose nanofibrils for potential periodontal treatment

Article

Author: Ferreira, João O ; Carvalho, Ana C W ; Camargos, Camilla H M ; Francisco, Kelly R ; Rezende, Camila A ; de Freitas, Osvaldo ; Zambuzi, Giovana C ; Ferreira, Maíra P

The development of flexible and porous materials to control antibacterial delivery is a pivotal endeavor in medical science. In this study, we aimed to produce long and defect-free fibers made of zein and hydroxypropyl methylcellulose acetate succinate (HPMCAS) to be used as a platform for the release of metronidazole (MDZ) and metronidazole benzoate (BMDZ) to be potentially used in periodontal treatment. Microfibers prepared via electrospinning under a 2:3 (w/w) zein to HPMCAS ratio, containing 0.5 % (w/w) poly(ethylene oxide) (PEO) and 1 % (w/w) cellulose nanofibril (CNF) were loaded with 40 % (w/w) MDZ, 40 % (w/w) BMDZ, or a combination of 20 % (w/w) of each drug. The addition of CNF improved the electrospinning process, resulting in long fibers with reduced MDZ and BMDZ surface crystallization. MDZ- and BMDZ-incorporated fibers were semicrystalline and displayed commendable compatibility among drugs, nanocellulose and polymeric chains. Release tests showed that zein/HPMCAS/PEO fibers without CNF and with 20 % (w/w) MDZ/ 20 % (w/w) BMDZ released the drug at a slower and more sustained rate compared to other samples over extended periods (up to 5 days), which is a favorable aspect concerning periodontitis treatment.

100 Deals associated with Metronidazole Benzoate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08214	Metronidazole Benzoate	-	DB15759

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Amebiasis	CN	-	26 Nov 2002
Anaerobic bacterial infection	CN	-	26 Nov 2002
Balantidiasis	CN	-	26 Nov 2002
Dracunculiasis	CN	-	26 Nov 2002
Giardiasis	CN	-	26 Nov 2002
Leishmaniasis, Cutaneous	CN	-	26 Nov 2002
Trichomonas Vaginitis	CN	-	26 Nov 2002